← Leaderboards
Marco Antonio Biamonte
Nanocomposix, Inc.
$5,727,635
Attributed
$5,998,965
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,998,965 · 7
By mechanism
R44$4,978,079 · 3
R41$463,056 · 2
N43$299,659 · 1
R43$258,171 · 1
Top collaborators
- Richard Kimo Baldwin2 shared
- Peter Uwe Fischer1 shared
Most similar at Nanocomposix, Inc.
Same institution · by research overlap
- Richard Kimo Baldwin$304,226
- Peter Uwe Fischer$468,283
Others in their field
Other Emerging Leaders on “Diagnostic Tests”
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,503,168
- Lynn Briscoe · Leidos Biomedical Research, Inc.$95,408,471
- Leonard Freedmand · Leidos Biomedical Research, Inc.$55,464,221
- Mark Marino · Venturewell$54,482,205
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Bala Raja · Luminostics, Inc.$28,624,460
Research focus
Diagnostic TestsDiagnosticAntibodiesAffectIgg4Pharmaceutical PreparationsSpecificityGlobal HealthAntigensProgramsFundingSecureInfectionSensitivity And SpecificityFilarial ElephantiasesProteinsNovel DiagnosticsPrototypeCountryCostAdvisory CommitteesPersonsDevicesCommercialization
Grant awards (11)
Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis$842,379
R44 · FY2025 · AI · contact PI
Supporting WHO Lymphatic Filariasis Elimination Programs: Progressing a Highly Sensitive and Specific Rapid Diagnostic Test for Brugia Species Infection to Commercialization Readiness$396,523
R44 · FY2025 · AI · contact PI
SUPPORTING WHO ONCHOCERCIASIS ELIMINATION PROGRAMS: PROGRESSING A HIGHLY SENSITIVE AND ULTRA-SPECIFIC RAPID DIAGNOSTIC TEST TO COMMERCIALIZATION READINESS$908,264
R44 · FY2024 · AI · contact PI
Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis$852,688
R44 · FY2024 · AI · contact PI
Supporting WHO Lymphatic Filariasis Elimination Programs: Progressing a Highly Sensitive and Specific Rapid Diagnostic Test for Brugia Species Infection to Commercialization Readiness$797,183
R44 · FY2024 · AI · contact PI
An Easy-to-Use, Low-Cost Triplex RDT for the Simultaneous Diagnosis of HBV, HCV, AND HIV Infection, Compatible with Field Use in LMICS and At-Home Use in the US$299,659
N43 · FY2024 · AI · contact PI
SUPPORTING WHO ONCHOCERCIASIS ELIMINATION PROGRAMS: PROGRESSING A HIGHLY SENSITIVE AND ULTRA-SPECIFIC RAPID DIAGNOSTIC TEST TO COMMERCIALIZATION READINESS$921,480
R44 · FY2023 · AI · contact PI
Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis$259,562
R44 · FY2022 · AI · contact PI
First-in-class, highly sensitive and specific rapid diagnostic test to detect Paragonimus infections$258,171
R43 · FY2022 · AI · contact PI
The first commercial rapid diagnostic test to detect Paragonimus infections$238,810
R41 · FY2019 · AI
Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis$224,246
R41 · FY2019 · AI